Value proposition

On August 12, 2022, Epizyme was acquired by Ipsen, expanding Ipsen’s oncology portfolio. Epizyme now operates as an Ipsen company with a shared goal of delivering innovative treatment options to underserved patients.

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Neuroscience is advancing at an unprecedented rate and Ipsen is at the forefront of this transformation.